NRX Pharmaceuticals Return On Equity vs. Number Of Shares Shorted
| NRXP Stock | USD 2.29 0.14 5.76% |
Return On Equity | First Reported 2010-12-31 | Previous Quarter 2.96 | Current Value 3.1 | Quarterly Volatility 1.99199002 |
For NRX Pharmaceuticals profitability analysis, we use financial ratios and fundamental drivers that measure the ability of NRX Pharmaceuticals to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well NRX Pharmaceuticals utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between NRX Pharmaceuticals's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of NRX Pharmaceuticals over time as well as its relative position and ranking within its peers.
NRX |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of NRX Pharmaceuticals. If investors know NRX will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about NRX Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of NRX Pharmaceuticals is measured differently than its book value, which is the value of NRX that is recorded on the company's balance sheet. Investors also form their own opinion of NRX Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is NRX Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because NRX Pharmaceuticals' market value can be influenced by many factors that don't directly affect NRX Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between NRX Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if NRX Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, NRX Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
NRX Pharmaceuticals Number Of Shares Shorted vs. Return On Equity Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining NRX Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare NRX Pharmaceuticals value to that of its competitors to determine the firm's financial worth. NRX Pharmaceuticals is rated below average in return on equity category among its peers. It is regarded third in number of shares shorted category among its peers . At this time, NRX Pharmaceuticals' Return On Equity is relatively stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value NRX Pharmaceuticals by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.NRX Number Of Shares Shorted vs. Return On Equity
Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
NRX Pharmaceuticals |
| = | -6.83 |
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
Number of Shares Shorted is the total amount of shares that are currently sold short by investors. When a stock is sold short, the short seller assumes the responsibility of repurchasing the stock at a lower price. The speculator will make money if the stock goes down in price or will experience a loss if the stock price goes up.
NRX Pharmaceuticals |
| = | 1.03 M |
If a large number of investors decide to short sell an equity instrument within a small period of time, their combined action can significantly affect the price of the stock.
NRX Number Of Shares Shorted Comparison
NRX Pharmaceuticals is currently under evaluation in number of shares shorted category among its peers.
NRX Pharmaceuticals Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in NRX Pharmaceuticals, profitability is also one of the essential criteria for including it into their portfolios because, without profit, NRX Pharmaceuticals will eventually generate negative long term returns. The profitability progress is the general direction of NRX Pharmaceuticals' change in net profit over the period of time. It can combine multiple indicators of NRX Pharmaceuticals, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Accumulated Other Comprehensive Income | -3.5 K | -3.6 K | |
| Interest Income | 495 K | 372.8 K | |
| Operating Income | -24.8 M | -26.1 M | |
| Income Before Tax | -27.1 M | -28.5 M | |
| Net Loss | -35.8 M | -37.6 M | |
| Net Loss | -27.1 M | -28.5 M | |
| Total Other Income Expense Net | -3 M | -3.1 M | |
| Income Tax Expense | -10.3 K | -10.9 K | |
| Net Interest Income | 590 K | 619.4 K | |
| Net Loss | -32.5 M | -34.1 M | |
| Non Operating Income Net Other | -272.7 K | -286.4 K | |
| Change To Netincome | 69.3 M | 39.4 M | |
| Net Loss | (4.58) | (4.35) | |
| Income Quality | 0.65 | 0.68 | |
| Net Income Per E B T | 0.90 | 0.60 |
NRX Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on NRX Pharmaceuticals. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of NRX Pharmaceuticals position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the NRX Pharmaceuticals' important profitability drivers and their relationship over time.
Learn to be your own money manager
Our tools can tell you how much better you can do entering a position in NRX Pharmaceuticals without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run ETFs Now
ETFsFind actively traded Exchange Traded Funds (ETF) from around the world |
| All Next | Launch Module |
Use Investing Themes to Complement your NRX Pharmaceuticals position
In addition to having NRX Pharmaceuticals in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Insurance Providers Thematic Idea Now
Insurance Providers
Companies providing all types of insurance and insurance services. The Insurance Providers theme has 44 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Insurance Providers Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Tools for NRX Stock Analysis
When running NRX Pharmaceuticals' price analysis, check to measure NRX Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NRX Pharmaceuticals is operating at the current time. Most of NRX Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of NRX Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NRX Pharmaceuticals' price. Additionally, you may evaluate how the addition of NRX Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.